545445-40-7

Basic information

• Product Name: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one
• Synonyms: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one;5,6-Dihydro-3-(4-morpholinyl)-2(1H)-pyridinone;3-Morpholino-5,6-dihydropyridin-2(1H)-one;5-morpholin-4-yl-2,3-dihydro-1H-pyridin-6-one
• CAS NO: 545445-40-7
• Molecular Formula: C₉H₁₄N₂O₂
• Molecular Weight: 182
• Mol File: 545445-40-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 432.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.195
• Storage Temp.: 2-8°C
• PKA: 14.66±0.40(Predicted)
• CAS DataBase Reference: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one(545445-40-7)
• EPA Substance Registry System: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one(545445-40-7)

Safety Data

• Hazardous Substances Data: 545445-40-7(Hazardous Substances Data)

Usage

General Description

3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one, also known as morantel, is a chemical compound commonly used as an anthelmintic agent in veterinary medicine to treat parasitic infections in livestock. Its molecular structure consists of a morpholine ring and a pyridin-2-one ring, making it a heterocyclic compound. Morantel works by interfering with the neurotransmission in the parasite's muscle cells, ultimately leading to paralysis and expulsion of the parasites from the host organism. It is known for its broad-spectrum activity against various internal parasites, including roundworms, hookworms, and certain species of flukes. Additionally, its low toxicity and minimal adverse effects make it a valuable therapeutic option for the treatment of parasitic infestations in animals.

InChI:InChI=1S/C9H14N2O2/c12-9-8(2-1-3-10-9)11-4-6-13-7-5-11/h2H,1,3-7H2,(H,10,12)

Upstream product

• 110-91-8 morpholine 
• 41419-12-9 3,3-dichloro-piperidin-2-one 
• 207976-92-9 3-chloro-5,6-dihydro-1H-pyridin-2-one 
• 675-20-7 piperidin-2-one 
• 1192-28-5 Cyclopentanone oxime 

Downstream Products

• 630382-44-4 1-(4-methoxyphenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one 
• 503614-56-0 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxylic acid ethyl ester 
• 1571062-06-0 (E)-1-(2-methyl-3-(3,4,5-trimethoxyphenyl)acryloyl)-3-morpholino-5,6-dihydropyridine-2(1H)-one 
• 1571062-07-1 (E)-morpholino-1-(2-ethyl-3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one 
• 1571062-08-2 (E)-morpholino-1-(2-propyl-3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one 
• 1571062-01-5 (E)-3-morpholino-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one 

Relevant articles and documents

Pyrazolo [3, 4 - c] pyridine - 7 - ketone compound and use thereof

Belonging to the technical field of medicine, the invention relates to a 4, 5-dihydro-1H-pyrazolo[3, 4-c]pyridine-7-one containing derivative shown as general formula I, and pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein the substituents A, R1 and R2 have meanings given in the specification. The preparation also relates to a preparation method of the general formula I compound and its pharmaceutically acceptable salt or prodrug, medicinal compositions containing the compound and application of the compound as an Xa factor inhibitor, especially application in preparation of drugs for treatment and/or prevention of thromboembolic diseases. (formula I).

HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or its phenyl ring, and a 4-10 membered heterocyclic ring or its benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; RI-3 are independently selected from H, F, Cl, Br, I, CN, OH, SH,NH2, CHO, COOH respectively, or selected from C1-10 alkyls or heteroalkyls optionally substituted by R01, C3-10 alkyls ring hydrocarbon groups or heterocyclic hydrocarbon groups, C1-10 alkyls or heteroalkyls substituted by C3-10 ring hydrocarbon groups or heterocyclic hydrocarbon group. The compound can be used as an anticoagulant for treating and preventing thrombotic disorders, and can meet the real needs of selectivity and a potent inhibitor for coagulation Xa.

Pyrazole substituent comprising cyclonexane and piperidine ketone compound, and its composition and use thereof

The invention relates to a pyrazolo piperidone compound and a pharmaceutically acceptable composition thereof and application thereof to preparation of medicaments for treating diseases associated with an Xa factor. In particular, the invention relates to a novel pyrazolo piperidone compound containing a cyclohexane substituent, the pharmaceutical composition containing the compound, and application of the compounds to preparation of medicaments for treating diseases associated with the Xa factor.